2025
Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis
Chow R, Basu A, Kaur J, Hui D, Im J, Prsic E, Boldt G, Lock M, Eng L, Ng T, Zimmermann C, Scotte F. Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care In Cancer 2025, 33: 193. PMID: 39953210, PMCID: PMC11828838, DOI: 10.1007/s00520-025-09251-w.Peer-Reviewed Original ResearchConceptsChemotherapy-induced nausea and vomitingEfficacy of cannabinoidsTHC:CBDMeta-analysisPrevention of chemotherapy-induced nausea and vomitingProphylaxis of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting controlControlled TrialsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsNausea and vomitingChemotherapy-induced nauseaMethodsA literature searchCochrane Central RegisterComplete responseRandomized Controlled TrialsNo vomitingAdjunctive therapyRescue medicationAntiemetic regimensComposite endpointSubgroup analysisCannabinoidSecondary prevention
2024
Health status outcomes after acute myocardial infarction in patients without standard modifiable risk factors
Ikemura N, Chan P, Gosch K, Nguyen D, Iv C, Khan M, Lu Y, Sawano M, Krumholz H, Spertus J. Health status outcomes after acute myocardial infarction in patients without standard modifiable risk factors. American Heart Journal 2024, 281: 123-132. PMID: 39638274, PMCID: PMC11810589, DOI: 10.1016/j.ahj.2024.11.018.Peer-Reviewed Original ResearchSeattle Angina QuestionnaireModifiable risk factorsHealth status outcomesBaseline SAQ scoresAcute myocardial infarctionStatus outcomesHealth statusRisk factorsSequential adjustmentSAQ scoresModifiable cardiovascular risk factorsHistory of coronary diseaseSAQ Summary ScoreHierarchical linear mixed modelsAcute myocardial infarction patientsCardiovascular risk factorsMyocardial infarctionSummary scoreSociodemographic characteristicsAngina QuestionnaireLinear mixed modelsDepressive symptomsU.S. hospitalsLong-term mortalitySecondary preventionIncidental Detection of Previously Unknown Strokes on Head CT Examinations: An Untapped Opportunity for Secondary Prevention
Kenny-Howell C, Dixe de Oliveira Santo I, Wira C, de Havenon A, Tu L. Incidental Detection of Previously Unknown Strokes on Head CT Examinations: An Untapped Opportunity for Secondary Prevention. Journal Of The American College Of Radiology 2024, 22: 461-470. PMID: 39571646, DOI: 10.1016/j.jacr.2024.11.010.Peer-Reviewed Original ResearchHead CT imagesEmergency departmentOld strokeSecondary preventionHead CTCT imagesRetrospective study of adult patientsImplement secondary preventionStudy of adult patientsAssociated with greater ageHead CT examinationsED careRisk of recurrent strokeED encountersUnivariate regressionCerebellar locationCT examinationsRetrospective studyAdult patientsIncidental detectionUnivariate analysisIncidental discoveryGreater ageMultivariate regressionPatientsAfter the Stroke (Secondary Prevention)
Bottomley S, Picagli J, Sico J. After the Stroke (Secondary Prevention). 2024, 445-457. DOI: 10.1007/978-3-031-66289-8_37.Peer-Reviewed Original ResearchBeta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Chi K, Lee P, Chowdhury I, Akman Z, Mangalesh S, Song J, Satish V, Babapour G, Kang Y, Schwartz R, Chang Y, Borkowski P, Nanna M, Damluji A, Nanna M. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. European Journal Of Preventive Cardiology 2024, 32: 633-646. PMID: 39298680, PMCID: PMC11922798, DOI: 10.1093/eurjpc/zwae298.Peer-Reviewed Original ResearchReduced ejection fractionBeta-blockersEjection fractionHeart failureMortality benefitBB useReduced EFCV mortalityPost-MIRandom-effects meta-analysisMeta-analysisHistory of HFAll-Cause MortalityTemporal trendsPrespecified subgroup analysesEvent-free periodCardiovascular (CVIncreased CV mortalityStudy inclusion periodPost-myocardial infarctionContemporary dataAssociated with detrimental effectsNon-significant trendSecondary preventionBB usersEfficacy of 5% methylene blue photodynamic therapy in the treatment of potentially malignant oral disorders: a randomized, double-blind, controlled trial
de Freitas Silva B, Rocha R, Prudente T, de Oliveira Lenza M, Ferraz D, Mezaiko E, do Couto Lima Moreira F, Yamamoto-Silva F. Efficacy of 5% methylene blue photodynamic therapy in the treatment of potentially malignant oral disorders: a randomized, double-blind, controlled trial. International Journal Of Clinical Trials 2024, 11: 207-214. DOI: 10.18203/2349-3259.ijct20242003.Peer-Reviewed Original ResearchMalignant oral disordersOral leukoplakiaPhotodynamic therapyOral disordersSecondary prevention of oral cancerMethylene blue photodynamic therapyDouble-blind clinical trialPrevention of oral cancerEfficacy of photodynamic therapyMalignant transformation rateAminolevulinic acidTreatment of OLClinical remissionDouble-blindCost of treatmentOral cancerClinical trialsPrimary outcomeSecondary outcomesSecondary preventionTreatment protocolsExtensive lesionsRisk factorsConventional treatmentControlled TrialsSecondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRisk AssessmentRisk FactorsSecondary PreventionStrokeUnited KingdomUnited StatesConceptsMyocardial infarctionPrevention scoreSecondary preventionImplementation of preventive therapyNational cohortUK BiobankAntiplatelet therapy useGuideline-directed therapyPrevention profilesBlood pressure controlAdherence to guideline-directed therapyLow-density lipoprotein controlNeighborhood deprivation levelHistory of strokeVascular risk profileStatin useAntiplatelet useTherapy usePreventive therapyComparison to participantsPrevention criteriaCross-sectional analysisBlood pressurePatientsPressure control
2023
Hospital‐Level Variability in Reporting of Ischemic Stroke Subtypes and Supporting Diagnostic Evaluation in GWTG‐Stroke Registry
Mullen M, Gurol M, Prabhakaran S, Messé S, Kleindorfer D, Smith E, Fonarow G, Xu H, Zhao X, Cigarroa J, Schwamm L. Hospital‐Level Variability in Reporting of Ischemic Stroke Subtypes and Supporting Diagnostic Evaluation in GWTG‐Stroke Registry. Journal Of The American Heart Association 2023, 12: e031303. PMID: 38108258, PMCID: PMC10863791, DOI: 10.1161/jaha.123.031303.Peer-Reviewed Original ResearchConceptsHospital-level variabilityDiagnostic evaluationIschemic strokeDiagnostic testingStroke pathogenesisCryptogenic strokeSecondary preventionEtiologic subtypesRisk factorsLarge nationwide registryIschemic stroke subtypesLong-term cardiac rhythm monitoringCardiac rhythm monitoringAdequate diagnostic evaluationIntracranial vascular imagingEvidence-based interventionsNationwide registryStroke subtypesIS subtypesDocumentation ratesRhythm monitoringPatientsCardiac monitoringSubtypesStrokeNational Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020
Lu Y, Liu Y, Dhingra L, Caraballo C, Mahajan S, Massey D, Spatz E, Sharma R, Rodriguez F, Watson K, Masoudi F, Krumholz H. National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020. JAMA Network Open 2023, 6: e2345964. PMID: 38039001, PMCID: PMC10692850, DOI: 10.1001/jamanetworkopen.2023.45964.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseHistory of ASCVDCross-sectional studyLifestyle modificationPharmacological medicationsOptimal careCurrent careUS adultsEthnic differencesWhite individualsGuideline-recommended therapiesTotal cholesterol controlNon-Hispanic white individualsNutrition Examination SurveyLatino individualsQuality of careSelf-reported raceStatin useRecommended TherapiesSecondary preventionCholesterol controlOptimal regimensSmoking cessationEligible participantsExamination SurveyComparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
Nogueira A, Barreto J, Moura F, Luchiari B, Abuhab A, Bonilha I, Nadruz W, Gaziano J, Gaziano T, de Carvalho L, Sposito A. Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model. Health Economics Review 2023, 13: 50. PMID: 37878108, PMCID: PMC10599033, DOI: 10.1186/s13561-023-00466-3.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGlucose-lowering therapyType 2 diabetesNetwork Meta-AnalysisSecondary preventionPrevalence of type 2 diabetesBrazilian public health systemRisk of cardiovascular outcomesPublic health systemCost-effectiveReduced relative riskNon-fatal cardiovascular eventsContext of primary preventionConclusionsIn BrazilClasses of glucose-lowering therapiesHealth systemManagement of T2DMGLP-1aCost-effectiveness modelStandard carePrimary preventionCost-effectiveness ratioRelative riskEvidence-basedInternational dollarsPatient knowledge and preferences for peripheral artery disease treatment
Smolderen K, Romain G, Gosch K, Arham A, Provance J, Spertus J, Poosala A, Shishehbor M, Safley D, Scott K, Stone N, Mena-Hurtado C. Patient knowledge and preferences for peripheral artery disease treatment. Vascular Medicine 2023, 28: 397-403. PMID: 37638882, PMCID: PMC10591804, DOI: 10.1177/1358863x231181613.Peer-Reviewed Original ResearchPeripheral artery diseaseTreatment goalsPatient knowledgeTreatment optionsTreatment preferencesHeart attack/strokeSymptomatic peripheral artery diseasePeripheral artery disease treatmentImportant treatment goalQuality of lifeCost of treatmentSpecific treatment goalsMulticenter registryPAD symptomsPain reliefSecondary preventionArtery diseaseTreatment choiceTreatment benefitPatient understandingPatientsMedical decision makingDisease managementClaudicationDisease treatmentAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, Raz I, Bohula E, Giugliano R, Park J, Feinberg M, Braunwald E, Morrow D, Sabatine M. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal Of The American College Of Cardiology 2023, 81: 2391-2402. PMID: 37344040, PMCID: PMC11466046, DOI: 10.1016/j.jacc.2023.04.031.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusSecondary preventionIschemic strokePredictor of MIValidation cohortClinical decision-makingRates of MIMyocardial infarctionAtherothrombotic eventsRisk quintileRisk of atherothrombotic eventsRisk modelSelection of pharmacotherapyRisk scoreAssessed clinical variablesMultivariate Cox regressionClinical trial cohortPooled cohortCandidate variablesCox regressionIS ratesDECLARE-TIMIAbsolute reductionTrial cohortCohortThe brown university cancer prevention and survivorship curriculum: A case study on program development in an internal medicine residency.
Francis E, Pounardjian T, Li J, Moku P, Avidan O, DeCarli K, Manzullo E, Sanft T, McGarry K, Dizon D, Duffy C. The brown university cancer prevention and survivorship curriculum: A case study on program development in an internal medicine residency. Journal Of Clinical Oncology 2023, 41: 11031-11031. DOI: 10.1200/jco.2023.41.16_suppl.11031.Peer-Reviewed Original ResearchCancer preventionCancer survivorsIM residentsEarly detectionMedicine residentsCancer care continuumQuality of lifeCancer control continuumClinical skillsHematology-oncology fellowsInternal medicine residency programsInternal medicine residentsSecondary preventionInternal medicine residencySurvivorship experienceMedicine residency programsProvider teamCare continuumLong-term effectsClinical experienceOncology fellowsHealth disparitiesPatientsPreventative servicesPreventionDiagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting: A Scientific Statement From the American Heart Association
Amin H, Madsen T, Bravata D, Wira C, Johnston S, Ashcraft S, Burrus T, Panagos P, Wintermark M, Esenwa C, Disease O. Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting: A Scientific Statement From the American Heart Association. Stroke 2023, 54: e109-e121. PMID: 36655570, DOI: 10.1161/str.0000000000000418.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic attackMaximal medical therapyHigh-risk patientsCorrect clinical diagnosisRisk stratification scaleAmerican Heart AssociationEmergency department settingFuture cerebrovascular eventsScientific statementTime of evaluationCerebrovascular eventsSecondary preventionStroke riskMedical therapyNeurological examinationAcute phaseIndex eventHeart AssociationDepartment settingPatient educationAncillary testingCerebral vasculatureConfirmatory testingClinical diagnosis
2022
Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer
Chin C, Damast S. Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer. Brachytherapy 2022, 22: 30-46. PMID: 36567175, DOI: 10.1016/j.brachy.2022.10.012.Peer-Reviewed Original ResearchConceptsSexual morbidityCervical cancerSexual sequelaeImage-guided adaptive brachytherapyQuality of lifeSecondary preventionCurative treatmentDosimetric factorsCommon symptomsVaginal doseCancer patientsClose surveillanceSexual functionIndirect sequelaeSexual symptomsVaginal morbidityVaginal toxicitySexual dysfunctionAdaptive brachytherapySexual healthClinical interventionsMorbidityCritical organsSequelaeEffect relationshipA Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease
Al-Abdouh A, Mhanna M, Jabri A, Ahmed T, Altibi A, Ghanem F, Alhuneafat L, Mostafa M, Abusnina W, Dewaswala N, Bhopalwala H, Kundu A, Michos E. A Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease. American Journal Of Therapeutics 2022, 31: e193-e195. PMID: 36857708, DOI: 10.1097/mjt.0000000000001583.Peer-Reviewed Original ResearchAcute pancreatitis precedes chronic pancreatitis in the majority of patients: Results from the NAPS2 consortium
Singh V, Whitcomb D, Banks P, AlKaade S, Anderson M, Amann S, Brand R, Conwell D, Cote G, Gardner T, Gelrud A, Guda N, Forsmark C, Lewis M, Sherman S, Muniraj T, Romagnuolo J, Tan X, Tang G, Sandhu B, Slivka A, Wilcox C, Yadav D, Wilcox C, Guda N, Banks P, Conwell D, Lo S, Gelrud A, Gardner T, Baillie J, Forsmark C, Muniraj T, Sherman S, Singh V, Lewis M, Romagnuolo J, Hawes R, Cote G, Lawrence C, Anderson M, Amann S, Etemad B, DeMeo M, Kochman M, Abberbock J, Barmada M, Bauer E, Brand R, Kennard E, LaRusch J, O'Connell M, Stello K, Slivka A, Talluri J, Tang G, Whitcomb D, Wisniewski S, Yadav D, Burton F, AlKaade S, DiSario J, Sandhu B, Money M, Steinberg W. Acute pancreatitis precedes chronic pancreatitis in the majority of patients: Results from the NAPS2 consortium. Pancreatology 2022, 22: 1091-1098. PMID: 36404201, PMCID: PMC10122210, DOI: 10.1016/j.pan.2022.10.004.Peer-Reviewed Original ResearchConceptsDiagnosis of CPAcute pancreatitisChronic pancreatitisCP diagnosisAP patientsAssociation of APNorth American Pancreatitis StudiesMajority of patientsMultivariable logistic regressionDisease-related factorsNorth American cohortClinical acute pancreatitisAP episodeAbdominal painSecondary preventionMultivariable analysisExocrine insufficiencyPancreatic atrophyMore episodesUS CentersWhite raceLower oddsPatientsAmerican cohortPancreatitisAnalysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke
Xian Y, Xu H, Matsouaka R, Laskowitz D, Maisch L, Hannah D, Smith E, Fonarow G, Bhatt D, Schwamm L, Mac Grory B, Feng W, Fosbøl E, Peterson E, Johnson M. Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke. JAMA Network Open 2022, 5: e2224157. PMID: 35900761, PMCID: PMC9335137, DOI: 10.1001/jamanetworkopen.2022.24157.Peer-Reviewed Original ResearchConceptsAHA/ASA guidelinesAcute ischemic strokeMinor ischemic strokeUse of DAPTDual antiplatelet therapyIschemic strokeMinor strokeHospital-level variationAntiplatelet therapyASA guidelinesDAPT useCohort studySecondary preventionOdds ratioAmerican Heart Association/American Stroke AssociationMinor acute ischemic strokeMulticenter retrospective cohort studyMultivariable logistic regression analysisSubstantial hospital-level variationAHA/ASAGuidelines-Stroke programIdentical clinical featuresRetrospective cohort studyAmerican Stroke AssociationEvidence-based guidelinesPharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106520. PMID: 35523052, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106520.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPlatelet aggregation testCardioembolic strokePlatelet aggregationFXa inhibitorsOral anticoagulantsStroke patientsPharmacological differencesAdenosine diphosphateAggregation testConcurrent antiplatelet therapyIschemic stroke patientsCardioembolic stroke patientsOnset of symptomsResults Six patientsLight transmission aggregometryFactor Xa inhibitorsAntiplatelet therapySecondary preventionSix patientsAntiplatelet drugsAtrial fibrillationAntiplatelet effectXa inhibitorsDabigatranEvaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke
Xian Y, Xu H, Smith E, Fonarow G, Bhatt D, Schwamm L, Peterson E. Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. JAMA Internal Medicine 2022, 182: 559-564. PMID: 35344009, PMCID: PMC8961397, DOI: 10.1001/jamainternmed.2022.0323.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply